Black Diamond Therapeutics (BDTX) Gains from Investment Securities: 2018-2024
Historic Gains from Investment Securities for Black Diamond Therapeutics (BDTX) over the last 6 years, with Dec 2024 value amounting to $249,000.
- Black Diamond Therapeutics' Gains from Investment Securities fell 152.50% to -$105,000 in Q4 2021 from the same period last year, while for Dec 2021 it was $110,000, marking a year-over-year decrease of 98.70%. This contributed to the annual value of $249,000 for FY2024, which is N/A change from last year.
- As of FY2024, Black Diamond Therapeutics' Gains from Investment Securities stood at $249,000, which was up 1,656.25% from -$16,000 recorded in FY2022.
- Black Diamond Therapeutics' 5-year Gains from Investment Securities high stood at $8.5 million for FY2020, and its period low was -$90,000 during FY2021.
- Over the past 2 years, Black Diamond Therapeutics' median Gains from Investment Securities value was $116,500 (recorded in 2022), while the average stood at $116,500.
- Per our database at Business Quant, Black Diamond Therapeutics' Gains from Investment Securities surged by 16,515.69% in 2020 and then plummeted by 101.06% in 2021.
- Over the past 4 years, Black Diamond Therapeutics' Gains from Investment Securities (Yearly) stood at $8.5 million in 2020, then slumped by 101.06% to -$90,000 in 2021, then surged by 82.22% to -$16,000 in 2022, then reached $249,000 in 2024.